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Optimal management of clinically localised prostate cancer presents unique challenges, because of its highly variable and often
indolent natural history. There is an urgent need to predict more accurately its natural history, in order to avoid unnecessary
treatment. Medical records of men diagnosed with clinically localised prostate cancer, in the UK, between 1990 and 1996 were
reviewed to identify those who were conservatively treated, under age 76 years at the time of pathological diagnosis and had a
baseline prostate-specific antigen (PSA) measurement. Diagnostic biopsy specimens were centrally reviewed to assign primary and
secondary Gleason grades. The primary end point was death from prostate cancer and multivariate models were constructed to
determine its best predictors. A total of 2333 eligible patients were identified. The most important prognostic factors were Gleason
score and baseline PSA level. These factors were largely independent and together, contributed substantially more predictive power
than either one alone. Clinical stage and extent of disease determined, either from needle biopsy or transurethral resection of the
prostate (TURP) chips, provided some additional prognostic information. In conclusion, a model using Gleason score and PSA level
identified three subgroups comprising 17, 50, and 33% of the cohort with a 10-year prostate cancer specific mortality of o10, 10–
30, and 430%, respectively. This classification is a substantial improvement on previous ones using only Gleason score, but better
markers are needed to predict survival more accurately in the intermediate group of patients.
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The natural history of prostate cancer is highly variable and
difficult to predict. Over treatment of asymptomatic patients is a
serious problem leading to substantial morbidity. Introduction
of prostate-specific antigen (PSA) testing in some countries has
exacerbated this problem, leading to a much higher reported
incidence rate, but having little influence on mortality rates (Evans
and Møller, 2003). In the United States, where PSA testing has been
common, the incidence to mortality ratio is about 7.6. Conversely,
in the United Kingdom, where PSA testing is not performed
routinely, the ratio is approximately 2.5. Autopsy series have
confirmed that histologically proven prostate cancer can be
identified in approximately 40% of men over 50 years of age
who die of other causes (Breslow et al, 1977; Sakr et al, 1994). This
is about four times higher than the lifetime risk for American men
to be diagnosed with prostate cancer (approximately 11%),
indicating that more intensive screening is likely to uncover even
more indolent disease. This had led many countries, in particular
the United Kingdom, to endorse a more conservative approach to
disease detection and management. In the UK, PSA screening
is not endorsed by the health service (although it is available
on request) and radical prostatectomy or radiation therapy is not
common practice. However, this approach is not without
problems, since a substantial proportion of men develop
progressive disease from which they ultimately die. Furthermore,
conservative management can lead to considerable anxiety,
especially when the clinical outcome is so uncertain.
Several studies have attempted to document the long-term risk
of metastases and death from prostate cancer in men with
conservatively managed, clinically localised cancers (Chodak
et al, 1994; Albertsen et al, 1995, 1998, 2005a; Adolfsson et al,
1997; Holmberg et al, 2002; Johansson et al, 2004; Bill-Axelson
et al, 2005). Two of these (Albertsen et al, 1998; Johansson et al,
2004) estimated outcome based on histological tumour grade, but
did not include either clinical stage or initial serum PSA level
and reviewed Gleason grades. The former (Albertsen et al, 1998)
reported long-term outcomes for 767 men aged 55–74 years at
diagnosis with conservatively treated clinically localised prostate
cancer. Men with cancers that have Gleason scores of 2–4, 5, 6, 7,
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sand 8–10 had a 4–7, 6–11, 18–30, 42–70, and 60–87%
chance, respectively, of dying from prostate cancer within 15
years of diagnosis, depending on their age at diagnosis. Their
revised estimate of 20-year survival (Albertsen et al, 2005a)
indicated that annual mortality rates remained stable after 15 years
from diagnosis. In contrast to these findings, the latter study
(Johansson et al, 2004) reported an approximately three-fold
increase in the rate of progression and prostate cancer-specific
mortality rate after 15 years among their small cohort of 223
patients.
The first randomised trial of primary treatment with curative
intent for men with localised prostate cancer was reported by
Holmberg et al (2002) and later by Bill-Axelson et al (2005). This
trial included 695 men, with clinically localised prostate cancer,
randomised to either radical prostatectomy or no initial treatment
with systemic treatment deferred until the development of
symptomatic progression. The authors found a reduced risk of
progression and death from prostate cancer in the radically treated
men, but concluded that the disease-specific benefits of radical
prostatectomy must be weighed carefully against the potential
impact that surgery can have on quality of life. Other studies
(Chodak et al, 1994; Albertsen et al, 1995, 1998, 2005a; Adolfsson
et al, 1997; Holmberg et al, 2002) have concluded that watchful
waiting or no initial treatment with treatment delayed until the
development of symptomatic metastatic disease remains a viable
treatment option.
These studies emphasise the varied natural history of clinically
localised prostate cancer, especially for the intermediate risk
prostate cancers with Gleason score 6–7.
A basic tenet of an effective screening programme is that the
natural history of the disease should be understood well and that
early detection can have an important impact on outcome. Neither
of these requirements has been satisfied for prostate screening.
This study was performed to evaluate the utility of whether other
factors such as PSA, clinical stage and extent of disease could
provide useful prognostic information in addition to histological
grade.
MATERIALS AND METHODS
Study population and data collection
This was a population-based study in which potential cases were
identified from six cancer registries in Great Britain. Within each
region, collaborating hospitals were sought and cases from these
hospitals were reviewed. National approval was obtained from
the Northern Multi-Research Ethics Committee, followed by local
ethics committee approval at each of the collaborating hospital
trusts (Appendix A).
Men were included in this study if they were under age 76 years
at the date of diagnosis and had clinically localised prostate cancer
diagnosed by transurethral resection of the prostate (TURP) or
needle biopsy. Diagnosis between 1990 and 1996 (inclusively) and
a baseline PSA were required.
Patients treated by radical prostatectomy or radiation therapy
within 6 months of diagnosis were excluded. In addition, those
with objective evidence of metastatic disease (by bone scan, X-ray,
radiograph, CT scan, MRI, bone biopsy, lymph node biopsy, pelvic
lymph node dissection) or clinical indications of metastatic disease
(including pathologic fracture, soft tissue metastases, spinal
compression, or bone pain), or a PSA measurement over
100ngml
 1 at or within 6 months of diagnosis were also excluded.
These exclusions were a pragmatic method of focusing the study
on patients who were very likely to have truly localised disease at
presentation. Men who had hormone therapy prior to diagnostic
biopsy were also excluded, because of the influence of hormone
treatment on interpreting Gleason grade. We also excluded men
who died within 6 months of diagnosis, or had less than 6 months
of follow-up.
Registry data had limited utility for eliminating ineligible cases,
thus a review of hospital records was necessary to establish
eligibility. The review process and selection of cases is summarised
in Figure 1.
Registry data collection officers and trained medical staff
conducted on-site medical record reviews at each of 51 hospital
trusts (Appendix A).
Clinical staging was centrally reviewed and, where unstated in
the notes, was assigned, where possible, by an urologist based on
the reported findings. In approximately 24% of cases, no
information was available and in a further 16% of cases, stage
could not be assigned. In both circumstances, these cases were
designated Tx.
Original histological specimens from the diagnostic procedure
(needle biopsy or TURP) were requested, collected, and centrally
reviewed by a panel of expert urological pathologists to confirm
the diagnosis and, where necessary, to reassign Gleason grades
for all the prostate cancers using a conventional interpretation
(Deshmukh and Foster, 1997) of the Gleason grading
system. Approximately 12% of requested specimens were missing
or unidentifiable in hospital pathology databases. A further
17% of cases had no Gleason grade assigned for a variety of
reasons (Figure 1). Outcomes were determined through medical
records and cancer registry data. In January 2005, the
cancer registries were queried to obtain the most up-to-date
survival data. Date of last follow-up was different for each cancer
registry; the earliest was March 2004 and the latest was January
2005. Where available, death certificates for deceased patients
were reviewed to verify cause of death. Deaths were divided into
two categories, death from prostate cancer and death from
other causes, according to standardised World Health Organisa-
tion criteria. Patients still alive at last follow-up were censored at
that date.
Disease progression (treatment failure) was defined as clinical,
histological, or radiographic evidence of metastatic disease (lymph
node, bone, or soft tissue); or institution of additional hormone
therapy, radiation therapy, surgery, chemotherapy, or death
certified to be from prostate cancer.
Statistics
The primary end point to this study was time to death
from prostate cancer. An initial analysis characterised patient
status at different follow-up times (death from prostate cancer,
death from other causes, alive with progression, alive without
progression) in which censoring was done only if alive
and progression free at last follow-up. Subsequent analyses of
the main end points were performed by proportional hazards
models, censoring at the time of death from other causes, or
latest follow-up time. All follow-up times commenced at the
point of 6 months following diagnosis. The following variables
were recorded: Gleason score, all available PSA values, clinical
stage, extent of disease (proportion of TURP chips with disease or
linear proportion of needle biopsy containing disease), age at
diagnosis, method of diagnosis (TURP or needle biopsy), and
initial treatment (no initial treatment or early hormone manage-
ment). Baseline PSA was defined as the last PSA value within 6
months of diagnosis (including pre-diagnostic values), but before
initiation of hormone therapy and at least 3 weeks after any biopsy.
Patients for which any of these values greater than 100ngml
 1
were excluded.
Variables were first examined separately and then multivariate
models were constructed by a forward stepwise selection method.
For the multivariate models, a single linear trend variable across
categories was used for assessing the importance of a new variable.
If the variable was included, a second variable indicating missing
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s(unassigned) data was added before proceeding to examine further
variables. This was done to avoid loss of patients when one
variable was missing. A predictor was developed using Gleason
score and separate categories of PSA to create prognostic groups.
All P-values are two-sided and 95% confidence intervals were
based on the normal distribution with parameters derived from
partial likelihood calculations.
RESULTS
Cohort assembly
The process of identification of eligible patients is summarised in
Figure 1.
Of 2333 men eligible for evaluation, 1663 were managed by no
initial treatment and 670 were managed by early hormone therapy.
Overall, the median age at diagnosis was 70.1 years (range 44–76
years) and the median follow-up was 117 months (range 88–180
months). Most men (80%) were diagnosed after age 65 years. A
competing risk analysis showed that after 10 years of follow-up,
55% of the men had died, 24% from prostate cancer and 31% from
other causes and only 22% were still alive without progression
(Figure 2).
Early hormone therapy treated patients were diagnosed more
recently and had a shorter follow-up time, but the age at diagnosis
was similar for both cohorts (P¼0.25). Diagnosis was made by
not yet revie ed
N (%)
Cases not requested 203 (9)
Excluded on review:
Unknown, missing histology slides 284 (12)
Incorrect pathology specimen 43 (2)
 Histologically negative 135 (6)
No histology tissue left in block    6 (<1)
 Histologically ungradeable Gleason score  6 (<1)
Excluded, inorder of exclusion:
No biopsy record 3063 
Biopsy date not between 1990 and 1996 87
Age 76 years    78
No baseline PSA  1773
 Curative surgery within 6 months  148
Radiation therapy within 6 months 214
 Metastasis within 6 months   301
Death within 6 months 28 
 Prior invasive cancer with in 5 years 35
Hormone therapy before biopsy 56
 Less than 6 months follow-up data   2
diagnosed between 1990 and 1996, aged <76 years
Identified by collaborating UK cancer registries, as
N = 36 201
Listed as potentially eligible for
review
N =11 189
Excluded by registries on grounds of
radical treatment recorded, difficult
geographical access to hospital and
hospitals not participating
N = 25 012
Medical records reviewed
N = 8118
Records not accessed, because 
of registry staffing and time
restraints
N = 3071
Eligible patients
N =2333
Cases with reviewed histology
and Gleason score
N =1656 
Figure 1 Cohort assembly.
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Figure 2 Proportion of patients either dead from prostate cancer, dead
from any cause, or dead, progressed or with treatment failure, at different
follow-up times.
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sTURP in 1255 men (54%), needle biopsy in 1039 men (45%) and
was unspecified in 39 men (1%). Patients treated early by hormone
manipulation had a worse prognosis, even after multivariate
adjustment. Consequently, results are also given separately for the
two methods of initial management.
The distribution of baseline factors and the univariate risk of
death from prostate cancer for these factors are shown in Table 1.
Separate analyses for patients with early hormone therapy and no
initial treatment are given in Appendix A (Table A1).
Gleason grade
Reviewed Gleason scores were available for 71% of the total
cohort, 71% of those treated by no initial treatment, and 72% of
Table 1 Univariate analysis of factors influencing death from prostate cancer in men with conservatively managed clinically localised prostate cancer (total
eligible cohort¼2333)
Variable N (%)
Hazard ratio
(95% CI)
Prostate cancer death
at 10 years (%)
Gleason score
a
p5 61 (3) 0.59 (0.2–1.6) 8
6 681 (29) 1
b 13
7 500 (21) 2.30 (1.7–3.1) 29
8 250 (11) 3.89 (2.8–5.3) 41
9 or 10 164 (7) 8.22 (6.0–11.3) 61
Unassigned
c 677 (29) 2.55 (1.9–3.4) 31
w
2 (trend)¼186
Serum PSA (ngml
 1)
p4 546 (23) 1
b 14
44–10 502 (21) 1.34 (1–1.9) 19
410–25 607 (26) 2.05 (1.5–2.8) 28
425–50 400 (17) 3.19 (2.4–4.3) 38
450–100 278(13) 5.06 (3.7–6.8) 54
w
2 (trend)¼153
Clinical stage
T1 506 (22) 0.4 (0.3–0.5) 13
T2 612 (26) 1
b 30
T3 269 (12) 1.67 (1.3–2.2) 40
Tx
c 946 (40) 0.94 (0.8–1.2) 30
w
2 (trend)¼32
Cancer in biopsy (%)
p6 341 (15) 1
b 11
46–20 386 (17) 1.47 (0.9–2.3) 16
420–40 278 (12) 2.89 (1.9–4.4) 32
440–75 336 (14) 3.56 (2.4–5.3) 34
475–100 313 (13) 4.90 (3.3–7.2) 43
Unspecified
c 679 (29) 2.91 (2–4.2) 30
w
2 (trend)¼105
Age (years)
p65 474(20) 0.72 (0.6–0.9) 21
465–70 665 (29) 1
b 25
470–73 594 (25) 1.1 (0.9–1.4) 28
473–76 600 (26) 1.41 (1.1–1.8) 35
w
2 (trend)¼25
Year of diagnosis
1990 54 (2) 1.14 (0.7–2) 29
1991 109 (5) 1.35 (0.9–2) 32
1992 225 (10) 1.44 (1–2.0) 33
1993 346 (15) 1.29 (1–1.7) 32
1994 471 (20) 1.02 (0.8–1.4) 24
1995 551 (24) 1.05 (0.8–1.4) 23
1996 577 (2) 1
b (not yet achieved)
w
2 (trend)¼5.4
Method of diagnosis
Needle Biopsy 1039 (45) 1
b 31
TURP 1255 (54) 0.81 (0.7–1) 25
Unspecified
c 39 (1) 0.95 (0.5–1.8) 27
w
2¼4.7
Baseline hormones
No 1663 (71) 1
b 20
Yes 670 (29) 2.6 (2.2–3.1) 46
w
2¼113
CI denotes confidence interval.
aScore assigned during histopathological review.
bReference category.
cThese cases were excluded from the trend analysis. PSA denotes prostate
specific antigen. TURP denotes trans urethral resection of the prostate.
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sthose treated by early hormone therapy. Gleason score had
the greatest discriminating power, even though this was based
on a subset of the cohort (Table 1). A clear gradation was
seen across groups with a w
2 (trend) of 186, in the total cohort,
for prostate cancer death. The predictive power was weaker in
patients initially treated by early hormone therapy, but was
still stronger than any other variable for this group. Patients,
whose histology was not available for review, were similar
to the overall group, with a survival curve very similar to
those with a Gleason score of 7. Those with a Gleason score
of 4 or 5 had a 10-year prostate cancer survival rate
of 92% compared to 41% for those with Gleason score 9 or 10.
We further subdivided the Gleason score 7 into 3þ4 and 4þ3, but
they behaved similarly (HR 2.17 vs 2.51, 10 years survival 73 vs
68% respectively).
Baseline PSA
Baseline PSA values were the second most useful variable and
almost as discriminating as Gleason score. The w
2 (trend) was 153
for prostate cancer death. Again, a clear gradient was seen with
survival at 10 years, being 86% for men with PSA values
o4ngml
 1, but only 46% for men with values between 50 and
100ngml
 1. Much of the impact of PSA was independent of
Gleason score, as can be seen from the multivariate analysis
(Table 2a). Low values were less predictive for patients treated by
early hormone management.
Clinical stage and extent of disease
A total of 1387 (60%) patients had sufficient information
available to assign a clinical stage. In univariate analysis, a clear
but smaller difference than for Gleason score or baseline PSA was
seen. Extent of disease proved to be more useful than clinical stage
for both cohorts (Table 1) and retained significance in multivariate
models.
Age, method, and year of diagnosis
Age had a clear effect on non-prostate cancer death as expected.
The 10-year death rates from other causes were 18, 30, 42, 47%
for ages o65, 65–70, 71–73, 74–75 respectively (w
2 (trend)¼104).
An effect was also seen for death from prostate cancer. How-
ever, no effect was seen on progression rates (data not
shown), suggesting this may represent confounding with other
established risk factors, or misclassification of cause of death in
the elderly.
Method of diagnosis (TURP or needle biopsy) and year of
diagnosis had little impact on outcome.
Multivariate model
A forward stepwise selection multivariate model was developed.
The variables were entered in the following order and their relative
strengths indicated by the increment in w
2 (Dw
2): Gleason Grade
(186.4), PSA (84), age (15.2), percentage cancer in the biopsy (9.8),
clinical stage (8.0), and year of diagnosis (2.8). Full details are
given in Appendix A (Table A2 (a)). Separate models for no initial
treatment and early hormone therapy are provided also in
Appendix A (Table A2 (b) and (c)).
The most predictive variable was Gleason score, followed
by baseline PSA, age, extent of disease, and clinical stage.
Method of initial treatment was also important, even after
adjustment for other factors, reflecting an additional selection
of poor risk patients among those given early hormone
therapy.
A multivariate model for prostate cancer death based only on
different levels of Gleason score and baseline PSA is shown in
Table 2a and b.
This was clearly better than the univariate models. Almost
all of the information was contained in Gleason score and baseline
PSA. With these two variables we were able to identify 17%
of the cohort for which the Gleason score wasp5 and
PSAo25ngml
 1 or the Gleason score was 6 and PSAp4ngml
 1
where prostate cancer mortality at 10 years was less than 10%
and 33% of the cohort with Gleason score 7 and PSA425ngml
 1,
or Gleason score 8 and PSA410ngml
 1, or Gleason scoreX9
where prostate cancer mortality at 10 years was greater than 30%.
This last group could be further split into a very poor prognostic
group (Gleason scoreX9 and PSA425ngml
 1) comprising 5% of
men with a 10-year prostate cancer mortality greater than 75%
(Table 2b).
The relative importance of death from prostate cancer vs other
causes over the first 10 years of follow-up for different prognostic
groups is shown (Figure 3) separately for men aged 70 years or less
and men aged more than 70 years, at diagnosis.
DISCUSSION
Prostate cancer is currently the second leading cause of cancer
death among men in both the UK and USA. However,
approximately half the men diagnosed with this disease do not
die from it, even in the absence of radical treatment (Satariano
Table 2b Predicted prostate cancer specific survival at 10 years based
on baseline PSA and Gleason score, in men with clinically localised disease
Gleason score
PSA (ngml
 1) 5 or less 6 7 8 9 or 10
p4 93 (2) 90 (14) 83 (4.1) 72 (2.2) 53 (0.9)
44–10 93 (1) 89 (11) 82 (4.7) 71 (1.9) 51 (1.3)
410–25 90 (0.4) 86 (10.9) 76 (8.9) 63 (4.2) 40 (2.5)
425–50 85 (0.2) 79 (3.7) 65 (7.3) 48 (4) 24 (2.5)
450–100 83 (0.1) 75 (1.6) 61 (5.2) 43 (2.8) 19 (2.6)
Three groups are identified with 10 year survival of X90, 70–89, and p70%.
The analysis is based on all patients for whom neither variable was missing
(n¼1656). Numbers in parentheses indicate the percentage of total cohort
in this group.
Table 2a Hazard ratios for multivariate model for prostate cancer death
based on Gleason score and PSA, in patients having both variables available
Prostate cancer death
Variable
Total
eligible
(N¼1656)
No initial
treatment
(N¼1176)
Initial
hormones
(N¼480)
Gleason score
a
p5 0.67 0.63 1.50
61
b 1
b 1
b
7 (3+4, 4+3) 1.77 1.88 1.13
8 (3+5, 4+4, 5+3) 3.00 3.26 1.79
9 or 10 5.96 6.77 3.56
Serum PSA (ngml
 1)
p41
b 1
b 1
b
44–10 1.06 0.81 1.05
410–25 1.42 1.60 0.65
425–50 2.23 1.67 1.73
450–100 2.62 1.92 1.67
aScore assigned during histopathological review.
bReference category.
Long-term outcome and prostate cancer
J Cuzick et al
1190
British Journal of Cancer (2006) 95(9), 1186–1194 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
set al, 1998). This makes counselling patients about management
difficult. Recent results from the Scandinavian Prostate Cancer
Study Group (Bill-Axelson et al, 2005) demonstrate a reduction in
metastatic disease and prostate cancer-specific mortality for
radical prostatectomy compared to watchful waiting, but the gains
are small and it is not clear which men will benefit in this. Our data
incorporate informative prognostic parameters not analysed in
previous studies on conservatively treated men. In agreement
with Albertsen et al (1995) and Johansson et al (2004), we found
Gleason score to be an important determinant of cancer-specific
mortality. In addition, we found baseline PSA level and to a lesser
extent clinical stage and extent of disease added further predictive
value. Importantly, the information contained in PSA levels was
largely independent of that available from Gleason score and vice
versa, so that using both variables produced a simple classification
into three groups with very different outcomes.
Compared to previous studies, there are several reasons why our
findings are more applicable to a man diagnosed with localised
prostate cancer in the modern era. Firstly, the incorporation of
PSA augments the prognostic stratification by histological grading
alone. Secondly, the Gleason scoring in our study more accurately
reflects current pathological grading methods. Multiple investiga-
tors have documented an upward shift in Gleason score over time
(Kondylis et al, 2003; Albertsen et al, 2005b) – not representative of
a change in biology, but of pathologists today being more likely to
assign higher Gleason scores. Albertsen et al (2005a,b) assigned
Age 70 years
Gleason score <7 Gleason score = 7 Gleason score >7 
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Figure 3 Proportion of patients dead from prostate cancer (dark grey), dead from other causes (light grey), at different follow-up times up to 10 years,
according to baseline PSA and Gleason score, separately for patients aged 70 years or less at diagnosis and patients aged more than 70 years at diagnosis.
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sGleason grades in 1990–1992 and 33% of patients had a Gleason
score of 5 or less compared to our study where only 3% patients
had this classification. Thirdly, in Albertsen’s cohort, 24% of
patients had a Charlson Index (Charlson et al, 1987) of two or
greater, considered to be ‘significant co morbidity’. Consequently,
the cohort represents probably a high proportion of patients not
medically suitable, or patients deciding not to opt for primary
curative therapy. Since conservative management was used for a
much broader group of patients in the United Kingdom, our
population-based cohort may be a more representative one for men
faced with the choice of conservative vs curative-intent therapy.
While 54% of our patients were diagnosed by TURP, which is much
higher than would be found in a contemporary series, this did not
have an impact on outcomes, PSA levels were on average also
higher than for current series, but there were sufficient numbers of
patients in all groups to obtain reliable prognostic information
across the full spectrum of values. Lastly, our cohort is more than
three times the size of previous studies, providing more accurate
estimates of risk and greater statistical power.
Kattan et al (1998) found clinical stage, PSA, and Gleason grade
to be parameters predictive of PSA recurrence for men treated by
radical prostatectomy. In our study, clinical stage provided only a
small additional amount of information on prostate cancer death.
However, our information on clinical stage was unavailable for
40% of the cohort, and were recorded, was limited and based on a
retrospective review of clinical notes from a variety of institutions.
It is possible that carefully collected and complete prospective
information would prove to be more prognostic. This is in contrast
to the data on PSA that was 100% complete and centrally reviewed
Gleason Grade, which was available for 71% of the cohort. Age was
a strong predictor of death from causes other than prostate cancer,
and provided some additional information on prostate cancer
mortality. However, it did not predict progression, and its effect on
prostate cancer mortality may reflect misclassification of cause of
death in these elderly men.
Our analyses identified 33% of men with poor 10-year cancer-
specific mortality (430%), where no initial treatment is not a good
option, especially when the risk of death from other causes is low.
We also identified a group comprising 17% of men where the
10-year cancer-specific survival was very good (490%). Long
follow-up will be needed to see if these men remain at low risk of
disease-related mortality, since it is not clear if mortality rate
trends will plateau or continue to increase. In the Swedish
(Johansson et al, 2004) cohort, cancer-specific mortality rates
increased during years 15–20 following diagnosis relative to the
initial 15 years, whereas Albertsen et al (2005a) found annual
cancer-specific mortality rates to be unchanged after 15 years.
In our study, approximately 50% of patients have what may be
considered an intermediate prognosis (10–30% 10-year cancer-
specific mortality), where better markers of disease progression are
needed. This applies especially to the 11% of men with Gleason
score 6 and PSA level 4–10ngml
 1, many of whom undoubtedly
have a very good prognosis. Currently, we are collecting all
available tumour blocks from the cohort to construct tissue micro-
arrays. It is hoped that identification of new markers with altered
DNA or protein expression in prostate cancer will help to highlight
disease destined to be clinically relevant, especially for this
intermediate group.
In conclusion, we have confirmed Gleason score as an important
prognostic factor for men with conservatively treated localised
prostate cancer and are the first to include PSA at diagnosis into
the prognostic model for these patients. While providing
valuable information for men considering or choosing conserva-
tive therapy, our study has also emphasised the urgent need to
identify better markers of tumour behaviour to assist in
formulating appropriate management of individual men with
prostate cancer.
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Appendix A
Members of the Transatlantic Prostate Group included listed
authors and investigators designated by an asterisk.
Table A1 Univariate analysis of factors influencing death from prostate
cancer in men with clinically localised prostate cancer, (a) and given no
initial treatment: N¼1663 and (b) initially treated with hormones: N¼670
Variable N (%)
Hazard ratio
(95% CI)
Prostate cancer death
at 10 years (%)
(a)
Gleason score
a
p5 57 (3) 0.59 (0.2–1.9) 6
6 589 (35) 1
b 10
7 313 (19) 2.24 (1.5–3.3) 23
8 136 (8) 3.84 (2.5–5.9) 38
9 or 10 81 (5) 8.64 (5.7–13.2) 53
Unassigned
c 487(29) 2.39 (1.7–3.4) 24
w
2 (trend)¼101
Serum PSA (ngml
 1)
p4 513 (31) 1
b 12
44–10 416 (25) 1.14 (0.8–1.7) 15
410–25 432 (26) 2.13 (1.5–3) 27
425–50 212 (13) 2.64 (1.8–3.9) 30
450–100 90 (5) 4.1 (2.6–6.3) 41
w
2(trend)¼56
Clinical stage
T1 435 (26) 0.42 (0.3–0.6) 10
T2 395 (24) 1
b 22
T3 126 (8) 1.69 (1.1–2.5) 33
Tx
c 707 (43) 1.02 (0.8–1.4) 24
w
2(trend)¼21
Cancer in biopsy (%)
p6 315 (19) 1
b 10
46–20 308 (19) 1.16 (0.7–2) 10
420–40 196 (12) 2.75 (1.7–4.5) 27
440–75 202 (12) 3.73 (2.3–6) 29
475–100 156 (9) 4.3 (2.6–7) 33
Unspecified
c 486 (29) 2.58 (1.7–4) 24
w
2¼59
Age (years)
p65 357 (21) 0.7 (0.5–1) 14
465–70 466 (28) 1
b 18
470–73 417 (25) 1.23 (0.9–1.7) 22
473–76 423 (25) 1.6 (1.2–2.2) 28
w
2 (trend)¼23
Year of diagnosis
1990 46 (3) 1.68 (0.9–3.2) 29
1991 86 (5) 1.73 (1.1–2.8) 30
1992 168 (10) 1.71 (1.1–2.6) 25
1993 266 (16) 1.27 (0.8–1.9) 22
1994 344 (21) 1.1 (0.7–1.7) 18
1995 370 (22) 0.97 (0.6–1.5) 15
1996 383 (23) 1
b (not yet achieved)
w
2 (trend)¼11
Method of diagnosis
Needle biopsy 611 (37) 1
b 23
TURP 1023 (61) 0.83 (0.7–1.1) 19
Unspecified
c 29 (2) 0.9 (0.4–2.2) 19
w
2¼1.9
Table A1 (Continued)
Variable N (%)
Hazard ratio
(95% CI)
Prostate cancer death
at 10 years (%)
(b)
Gleason score reviewed
a
p5 4 (1) 1.30 (0.2–9.7) —
6 92 (14) 1
b 39
7 187 (28) 1.28 (0.8–2.1) 40
8 114 (17) 1.92 (1.1–3.2) 46
9 or 10 83 (12) 3.82 (2.3–6.4) 68
Unassigned
c 190 (28) 1.78 (1.1–2.9) 48
w
2 (trend)¼33
Serum PSA (ngml
 1)
p4 33 (5) 1
b 36
44–10 86 (13) 1.03 (0.5–2.2) 40
410–25 175 (26) 0.79 (0.4–1.6) 32
425–50 188 (28) 1.42 (0.7–2.8) 48
450–100 188 (28) 1.95(1–3.9) 62
w
2 (trend)¼20
Clinical stage
T1 71 (11) 0.7 (0.4–1.2) 34
T2 217 (32) 1
b 44
T3 143 (21) 1.32 (0.9–1.9) 46
Tx
c 239 (36) 1.04 (0.8–1.4) 51
w
2(trend)¼2
Cancer in biopsy (%)
p6 26 (4) 1
b 33
46–20 78 (12) 1.13 (0.5–2.6) 40
420–40 82 (12) 1.41 (0.6–3.2) 44
440–75 134 (20) 1.28 (0.6–2.9) 40
475–100 157 (23) 1.87 (0.9–4.1) 53
Unspecified
c 193 (29) 1.56 (0.7–3.4) 48
w
2¼5.8
Age (years)
p65 117 (18) 0.88 (0.6–1.3) 42
465–70 199 (30) 1
b 42
470–73 177 (26) 1.0 (0.7–1.4) 46
473–76 177 (26) 1.24 (0.9–1.7) 54
w
2(trend)¼2.8
Year of diagnosis
1990 8 (1) 0.65 (0.2–2.1) 25
1991 23 (3) 1.18 (0.6–2.3) 40
1992 57 (9) 1.39 (0.9–2.3) 53
1993 80 (12) 1.75 (1.2–2.6) 63
1994 127 (19) 1.08 (0.7–1.6) 41
1995 181 (27) 1.16 (0.8–1.7) 40
1996 194 (29) 1
b (not yet achieved)
w
2(trend)¼1.7
Method of diagnosis
Needle biopsy 428 (64) 1
b 42
TURP 232 (35) 1.37 (1.1–1.8) 52
Unspecified
c 10 (1) 1.26 (0.5–3.1) 50
w
2¼4.8
CI denotes confidence interval.
aScore assigned during histopathological review.
bReference category.
cThese cases were excluded from the trend analysis.[2]PSA
denotes prostate-specific antigen. TURP denotes trans urethral resection of the
prostate.
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sInvestigators in participating regional cancer registries and
hospital trusts are listed below:
Thames Cancer Registry: Henrik Møller
*, Shirley Bell (de-
ceased), K Linklater, J Ottey V Fisher; Ashford & St Peter’s,
M Hall, N Harvey Hills; Barnet & Chase Farm, H Reid; Brighton
and Sussex, N Kirkham, P Thomas; Bromley, D Nurse; Dartford &
Gravesham, I Dickinson, P Thebe; East & North Hertfordshire,
D Hanbury, M Ali-Izzi; Eastbourne, C Moffatt; Epsom & St Helier,
M Bailey, L Temple; Essex Rivers Healthcare, W Aung, C. Booth;
Frimley Park, B Montgomery, P Denham; Greenwich Healthcare,
N Cetti, P Pinto; Guy’s & St Thomas’s, A Chandra, T O’Brien;
Hammersmith Hospitals, N Livni; Havering Hospitals,
I Saeed; Hillingdon, F Barker, T Beaven; King’s Healthcare,
G Muir, Z Khan; Kingston, C Jameson; Lewisham, A Giles; Mayday
Healthcare, N Arsanious, A Arnaout; The Medway, E Boye;
Mid Essex Hospitals; Mid Kent, M Boyle; North West London
Hospitals, M Jarmulowicz; Royal Free Hampstead, RJ Morgan,
A Bates; St Bartholomew’s and The Royal London Hospitals,
F Chinegwundoh, RTD Oliver, D Berney; Royal Surrey County, S
De Sanctis; Southend, M Chappell; St George’s, London, R Kirby, C
Corbishley; St Mary’s, London, A Patel, M Walker; West
Hertfordshire, J Crisp, W Riddle; Worthing & Southlands
Hospitals, J Grant.
Northern & Yorkshire Cancer Registry & Information Service:
David Forman
*, C Storer, C Bennett, C Spink; Airedale, I Appleyard,
J O’Dowd; Hull & East Yorkshire, J Hetherington, A MacDonald;
The Leeds Teaching Hospitals, P Whelan, P Quirke, P Harnden.
Oxford Cancer Intelligence Unit: Monica Roche
*, Sandra
Edwards, S Bose, P Hall; Heatherwood & Wexham Park, M Ali,
O Karim; Milton Keynes, E Walker, S Jalloh; Northampton, M
Miller, A Molyneux; Oxford Radcliffe, S Brewster, D Davies; Royal
Berkshire & Battle, P Malone, C McCormick; Stoke Mandeville,
J Greenland, A Padel
Welsh Cancer Intelligence & Surveillance Unit: John Steward
*,
Shelagh Reynolds, Lynda Roberts, Judith Adams; Ceredigion and
Mid Wales, J Edwards, CGB Simpson; Conwy & Denbighshire, A
Dalton, V Srinivasan; NE Wales, A De Bolla, C Burdge; Gwent
Healthcare, W Bowsher, M Rashid; Swansea, M Lucas, C O’Brien;
Cardiff & Vale, M Varma.
Scottish Cancer Registry: David Brewster
*; The Lothian Uni-
versity Hospitals, J Royle, K Grigor; North Glasgow University
Hospitals, D Kirk, A Milano, R Reid.
Merseyside & Cheshire Cancer Registry: Lyn Williams
*,R
Iddenden; Royal Liverpool University Hospital, CS Foster, P
Cornford.
Memorial Sloan Kettering Cancer Center: H Lilja*, S Eggener*.
Table A2 Multivariate model for prostate cancer death based on Gleason Grade (G), PSA (P), age (A), percentage cancer in biopsy(C), clinical stage (T),
year (Y) and (a) initial hormone treatment (H), (b) In patients with no initial treatment, and (c) Patients with initial treatment by early hormone therapy
Variables df N v
2 Dv
2 (1 df)
(a)
Total eligible cohort
G 1 1656 186.42 186.4
G Gm 2 2333 188.08
GG mP 3 2333 272.10 84.0
GG mPA 4 2333 287.34 15.2
G Gm P A (restricted – if C not missing) 4 1654 239.45
GG mPAC (restricted – if C not missing) 5 1654 249.20 9.8
G Gm P A C Cm (restricted – if T not missing) 6 1751 231.37
GG mPACC mT (restricted – if T not missing) 7 1751 239.34 8.0
G Gm P C Cm A T Tm 8 2333 305.12
GG mPCC mATT mY 9 2333 307.96 2.8
GG mPCC mATT mYH 10 2333 328.65 20.7
(b)
No initial treatment cohort
G 1 1176 100.53 100.5
G Gm 2 1663 104.07
GG mP 3 1663 130.72 26.7
GG mPA 4 1663 144.81 14.1
G Gm P A (restricted – if C not missing) 4 1177 117.64
GG mPAC (restricted – if C not missing) 5 1177 126.47 8.8
G Gm P A C Cm (restricted – if T not missing) 6 1219 111.29
GG mPACC mT (restricted – if T not missing) 7 1219 119.31 8.0
G Gm P C Cm A T Tm 8 1663 162.37
GG mPCC mATT mY 9 1663 166.25 3.9
(c)
Initial treatment cohort
G 1 480 33.39 33.4
G Gm 2 670 33.14
GG mP 3 670 50.67 17.5
GG mPA 4 670 54.28 3.6
G Gm P A (restricted – if C not missing) 4 477 52.66
GG mPAC (restricted – if C not missing) 5 477 52.85 0.2
G Gm P A C Cm (restricted – if T not missing) 6 532 46.11
GG mPACC mT (restricted – if T not missing) 7 532 46.73 0.6
G Gm P C Cm A T Tm 8 670 55.34
GG mPCC mATT mY 9 670 56.45 1.1
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